ASX All Ordinaries Stocks: Here’s Why These 8 Companies Joined the Club In the Latest Rebalance!

Twice a year, specifically on the third Fridays of March and September, the list of ASX All Ordinaries Stocks changes as stocks are added and demoted. Their promotions and demotions happen for various reasons that all feed into an increase or decrease in the company’s market capitalisation.

In this article, we look at 8 companies that will be promoted into the All Ords later in March 2026! This is not an exhaustive list, but it is the most prominant companies, in our view.

What are the Best ASX All Ordinaries Stocks to invest in right now?

Check our buy/sell tips

8 of the newest ASX All Ordinaries Stocks!

4DMedical (ASX: 4DX)

In September 2025, 4DX’s CT:VQ imaging software received FDA 510(k) clearance, thus becoming the world’s first and only non-contrast ventilation–perfusion lung imaging solution. Simultaneously, the US Centers for Medicare & Medicaid Services confirmed Medicare reimbursement for CT:VQ under Category III CPT codes, creating an immediate path to revenue.

The technology converts routine chest CT scans into detailed maps of lung airflow and blood perfusion without injections or additional equipment, targeting a US addressable market exceeding US$1.1bn annually. Early clinical partnerships with Stanford University and Brooke Army Medical Centre underpin credibility. The company raised A$79m follow-on capital to fund US commercialisation and scaled its salesforce accordingly.

In its February 2026 half-year results, 4DMedical reported revenue of A$2.85m against a wider net loss, but investors are pricing the future: the FDA clearance, CMS reimbursement support, and SaaS delivery model collectively transformed the investment narrative from a research-stage company to one with a commercial product in the world’s largest healthcare market. It will be one of the most promising medtechs in the All Ords!

Artrya (ASX: AYA)

Artrya’s elevation into the All Ordinaries was earned through back-to-back FDA clearances that fundamentally repositioned it as a commercial-stage cardiac AI company. In March 2025, the company secured FDA 510(k) clearance for its Salix Coronary Anatomy platform, enabling near real-time AI assessment of coronary CT angiography scans.

Just five months later in August 2025, Artrya received a second clearance for its Salix Coronary Plaque module which is an AI tool that detects high-risk coronary artery plaque, a key predictor of heart attack often missed in manual practice. This second approval automatically qualified the module for a Category I CPT reimbursement code worth US$950 per scan from January 2026, turning a cost centre into a revenue-generating tool for hospitals.

Artrya launched commercially into the US in July 2025, partnering with Tanner Health, Northeast Georgia Health System and Cone Health. An A$80mequity raise followed, fuelling US salesforce expansion. The shares rose approximately 530% in 2025 on the back of these milestones. A SAPPHIRE clinical study adds further scientific credibility and a pathway to commercialising within the largest US hospital network.

Acusensus (ASX: ACE)

Acusensus earned its place in the All Ordinaries on the strength of a sustained, contract-led revenue growth story that sets it apart from most ASX small caps. The Melbourne-based company, which deploys AI-powered camera systems to detect mobile phone use, seatbelt non-compliance, and speeding, posted a 20% revenue increase to A$59.4m FY25, driven by a raft of domestic and international contract wins. Its total contracted value since inception surged 84% year-on-year to A$376 million.

Its FY26 guidance was originally issued at A$79–84m and subsequently upgraded to A$83–87m after a series of new wins, including a A$44.7m, five-year NSW government contract, WA Road Safety Commission expansions, and a breakthrough US$22.6m five-year contract with the Connecticut Department of Transportation, Acusensus’s largest US deal to date.

The company raised A$30m in December 2025 to fund entry into emerging markets. Operating cash flow increased 131% to A$8.3m in FY25. The business is not yet deeply profitable, but its growing revenue visibility, government-backed recurring contracts, and international expansion (including New Zealand, the UK, and multiple US states) have given the market strong confidence in forward earnings momentum and the boost to enter the All Ords.

St George Mining (ASX: SGQ)

St George Mining’s entry into the All Ordinaries is the result of a transformative strategic pivot from nickel exploration to becoming one of the most talked-about rare earths and niobium developers on the ASX. After acquiring 100% of the Araxá Project in Brazil’s Minas Gerais state in February 2025, adjacent to CBMM’s world-leading niobium operations, the company embarked on an aggressive drilling campaign that rapidly revealed the project’s world-class scale.

A maiden JORC resource in April 2025 was followed by a 75% resource upgrade in March 2026, lifting the estimate to 70.91Mt at 4.06% TREO and 0.62% niobium pentoxide, with Measured and Indicated resources surging 218%. Step-out drilling discovered a significant new niobium zone 400 metres outside the existing resource boundary, with intercepts such as 81.5 metres at 1.27% Nb₂O₅ from surface, while the system remained open in all directions.

Geopolitical tailwinds amplified market interest: niobium is a US Top 10 critical metal with more than 90% of supply currently concentrated in Brazil, and St George has signed a strategic rare earths alliance with a US defence industry magnet manufacturer. Land secured near the project for future processing infrastructure signals near-term development ambitions.

Saluda Medical (ASX: SLD)

Saluda Medical’s rapid inclusion in the All Ordinaries comes barely 3 months after its debut, where it raised A$230.8m in Australia’s largest medtech IPO for the year. Some investors disappointed with its debut may question its place in the All Ords, but hear us out.

The Minneapolis-based company (originally developed in Australia with CSIRO backing) markets the Evoke System, the world’s first FDA-cleared closed-loop spinal cord stimulation (SCS) device. Unlike conventional SCS, the Evoke System reads and responds to the spinal cord’s evoked compound action potentials in real time, adjusting therapy pulse-by-pulse for each patient. Clinical data from the landmark EVOKE trial, published across The Lancet Neurology, JAMA Neurology, and Regional Anaesthesia and Pain Medicine, showed 83% of patients achieving at least 50% pain reduction at 36 months with zero explants due to loss of efficacy.

The company generated US$70.4m FY25 revenue (up 36% year-on-year) and is targeting US$81.9m in FY26. In January 2026, the next-generation EVA Sensing Technology received European CE certification following its December 2024 FDA clearance, opening commercial expansion into Europe and Australia.

The IPO attracted major institutional investors including Wellington Management, Fidelity, and T. Rowe Price, reflecting confidence in the Evoke platform’s growth trajectory in the chronic pain management market. Retail piled in too and even if shares did not go in the right direction, the company’s market capitalisation is All Ords material.

Sunrise Energy Metals (ASX: SRL)

Sunrise Energy Metals has undergone one of the most extraordinary re-ratings on the ASX over the past year, rising approximately 2,600% as a cascade of geopolitical and commercial catalysts repositioned it as a globally strategic scandium developer. Being the only legitimate scanadium player on the ASX is a fresh bonus, and so it was a question of when and not if it would make the ASX All Ords

The company’s Syerston project in New South Wales — backed by prominent Rich Lister Robert Friedland, holds one of the world’s largest and highest-grade scandium deposits, with a September 2025 resource update confirming 45.9m measured and indicated tonnes at 414 parts per million.

In October 2025, US defence contractor Lockheed Martin secured an option to purchase 25% of Syerston’s annual production as part of the new Australia-US critical minerals pact. The US Export-Import Bank expressed interest in providing up to US$67min debt financing which is roughly half the project’s development cost. China’s tightening of scandium export controls in April 2025 heightened Western urgency to secure alternative supply.

A completed feasibility study in March 2026 confirmed capital costs of US$120m, 60tpa production, and a 32-year mine life. CEO Sam Riggall subsequently stated the company expects to supply the US government’s proposed US$12bn critical minerals strategic stockpile, announced by President Trump in early 2026. This was the final catalyst that saw it earn an All Ords promotion!

Southern Palladium (ASX: SPD)

Southern Palladium’s addition to the All Ordinaries is a result of its development progress achieved at its 70%-owned Bengwenyama PGM project on South Africa’s Eastern Limb of the Bushveld Complex, the world’s most significant platinum group metals region.

SPD’s project hosts a Tier-1 resource of more than 40m ounces of PGMs including 21.7m ounces of UG2, and an Optimised Pre-Feasibility Study published in 2025 demonstrated staged development economics with US$857m NPV (after tax) at an IRR of 26.4%, with peak capex reduced by 38% to US$279m.

In May 2025, Bengwenyama received Environmental Authorisation under South Africa’s National Environmental Management Act with no objections lodged, a significant regulatory milestone. Southern Palladium fulfilled all outstanding conditions under the MPRDA for the granting of a Mining Right, depositing its environmental guarantee of R91m in October 2025.

A Definitive Feasibility Study is targeting completion in 2026, with a Final Investment Decision expected post-DFS. An A$20m placement in late 2025 attracted three new global institutional investors. Rising platinum and palladium prices, driven by supply deficits and emerging Asian investment and jewellery demand, have further enhanced the project’s commercial appeal as it approaches construction readiness.

And it is not as if there are that many PGM-exposed stocks in the All Ords anyway!

West Wits Mining (ASX: WWI)

West Wits Mining’s inclusion in the All Ordinaries is underpinned by an immanent tangible milestone that very few junior gold companies achieve: first production. The company’s Qala Shallows deposit (Phase 1 of the broader Witwatersrand Basin Project in South Africa’s Central Rand Goldfield) is targeting its first gold pour in March 2026, which would make it South Africa’s first new underground gold mine in 15 years.

An updated Definitive Feasibility Study published in mid-2025 revealed substantially improved project economics driven by higher gold prices, with post-tax NPV surging 97% to US$500m and an IRR of 81%, underpinned by a 58% increase in projected revenue to US$2.7bn and 88% higher free cash flow. In June 2025, the company secured a ZAR 875m (~US$50 million) syndicated loan from South Africa’s Industrial Development Corporation and Absa Bank, fully covering the project’s peak funding requirement.

The company’s broader Witwatersrand Basin tenure hosts 7.24Moz at 4.0 grams per tonne, a 44% resource increase announced in December 2025. With gold trading at record levels above US$4,800/oz and the Qala Shallows economics stress-tested at conservative prices, West Wits enters the All Ords as a near-term producer in one of the world’s most storied gold provinces.